Congress Requests Information on Regulation of CBD 


On July 27, 2023, a bipartisan group of lawmakers issued a Request for Information (RFI) regarding the regulation of hemp-derived CBD products. The RFI seeks to evaluate the possibility of establishing a comprehensive regulatory framework for CBD. Congress seeks insights on CBD market dynamics, regulatory pathways, product scope, safety concerns, risk-benefit profiles, quality controls, and form, packaging, accessibility, and labeling. They also want to understand federal-state interactions, the impact of state programs on CBD regulation, and seek feedback on restrictions for consumer safety and responsible CBD use.

The Agriculture Improvement Act of 2018 removed hemp and hemp-derived CBD from the Controlled Substances Act, granting FDA authority to regulate CBD in FDA-regulated products. However, the FDA has maintained that CBD cannot be marketed as a food additive or dietary supplement under existing law. This RFI follows the FDA’s announcement of its intent to collaborate with Congress to devise a legislative strategy for CBD product regulation.

Aimed Alliance responded to the RFI, urging Congress to address the regulatory gaps surrounding CBD-containing consumer products intended for human consumption. This entails either enacting new safeguards within the current regulatory frameworks for food, dietary supplements, and tobacco products, or establishing a dedicated regulatory framework tailored specifically to CBD-containing products, encompassing both ingestion and inhalation methods. Such measures are critical to ensure the safety, quality, and responsible use of CBD products while fostering innovation and consumer confidence in this rapidly evolving market landscape.

Read the Request for Information
Read Aimed Alliance Response to RFI Questions

Read Aimed Alliance’s 
Essential Labeling Requirements for Consumer Products Containing Cannabis-Derived Ingredients and Intended for Human Ingestion.

Read Aimed Alliance’s Essential Elements of a Regulatory Framework for Consumer Products Containing Cannabis-Derived Ingredients and Intended for Human Ingestion. 

Last Updated on August 30, 2023 by Aimed Alliance


Comments are closed.